General
Preferred name
VARENICLINE
Synonyms
CP 526555 ()
CP526555 ()
Champix tartrate ()
Chantix tartrate ()
CP 526555-18 ()
Varenicline (dihydrochloride) ()
Varenicline (Hydrochloride) ()
Varenicline (Tartrate) ()
CP 526555 (dihydrochloride) ()
CP 526555 hydrochloride ()
Chantix, Champix,CP 526555-18 ()
Chantix, Champix,CP 526555 dihydrochloride ()
Chantix, Champix,CP 526555 ()
Varenicline dihydrochloride ()
Varenicline Hydrochloride ()
Varenicline Tartrate (CP 526555-18) ()
Varenicline (CP 526555) dihydrochloride ()
VARENICLINE TARTRATE ()
Varenicline-d4 ()
P&D ID
PD013697
CAS
249296-44-4
866823-63-4
230615-23-3
375815-87-5
2183239-01-0
Tags
available
drug
Drug indication
Smoking dependence
Drug Status
approved
investigational
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Varenicline (CP 526555) is an orally active partial agonist of ¦Á4¦Â2 nicotinic acetylcholine receptor (¦Á4¦Â2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of ¦Á6¦Â2 nAChR and a full agonist of ¦Á6¦Â2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation[1][2][3][4][5].
DESCRIPTION Varenicline (CP 526555) is an orally active partial agonist of ¦Á4¦Â2 nicotinic acetylcholine receptor (¦Á4¦Â2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of ¦Á6¦Â2 nAChR and a full agonist of ¦Á6¦Â2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation[1][2][3][4][5].
PRICE 43
DESCRIPTION Varenicline (CP 526555) is a selective partial agonist of the ??4??2 nAChR and a full agonist of the ??3??4 nAChR and ??7 nAChR to help smokers with cardiovascular disease and COPD quit smoking.
DESCRIPTION Varenicline (CP 526555-18) is an orally active partial agonist of ¦Á4¦Â2 nicotinic acetylcholine receptor (¦Á4¦Â2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of ¦Á6¦Â2 nAChR and a full agonist of ¦Á6¦Â2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation[1][2][3][4][5].
PRICE 71
DESCRIPTION Varenicline dihydrochloride is a Selective ??4??2 nicotinic acetylcholine receptor partial agonist.
DESCRIPTION Varenicline (CP 526555) is an orally active partial agonist of ¦Á4¦Â2 nicotinic acetylcholine receptor (¦Á4¦Â2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of ¦Á6¦Â2 nAChR and a full agonist of ¦Á6¦Â2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation[1][2][3][4][5].
PRICE 34
DESCRIPTION Varenicline (CP 526555) is a selective partial agonist of the α4β2 nAChR and a full agonist of the α3β4 nAChR and α7 nAChR to help smokers with cardiovascular disease and COPD quit smoking. (TargetMol Bioactive Compound Library)
DESCRIPTION Varenicline dihydrochloride is an α4β2 nicotinic acetylcholine receptor partial agonist. Varenicline is a prescription medication used for smoking cessation. (BOC Sciences Bioactive Compounds)
DESCRIPTION Varenicline(CP 526555; Champix; Chantix) is a prescription medication used to treat smoking addiction. As a partial agonist it both reduces cravings for and decreases the pleasurable effects of cigarettes and other tobacco products. Through these mechanisms Varenicline(CP 526555; Champix; Chantix) can assist some patients to quit smoking. (BOC Sciences Bioactive Compounds)
DESCRIPTION Varenicline Tartrate (CP 526555-18) is a benzazepine derivative that functions as an ALPHA4/BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION. (TargetMol Bioactive Compound Library)
Compound Sets
16
AdooQ Bioactive Compound Library
A10966
BOC Sciences Bioactive Compounds
varenicline-dihydrochloride-cas-866823-63-4-55393
varenicline-hydrochloride-cas-230615-23-3-item-84-312697
Cayman Chemical Bioactives
15030
26102
CZ-OPENSCREEN Bioactive Library
DrugBank
DB01273
DrugBank Approved Drugs
DB01273
DrugMAP
DMMUOLJ
DrugMAP Approved Drugs
DMMUOLJ
EU-OPENSCREEN Bioactive Compound Library
EOS100901
Ki Database
varenicline
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1396
MedChem Express Bioactive Compound Library
HY-10021
HY-10019
HY-10019A
HY-10020
NPC Screening Collection
Other bioactive compounds
Selleckchem Bioactive Compound Library
Varenicline-tartrate
varenicline
varenicline-dihydrochloride
varenicline-hydrochloride
TargetMol Bioactive Compound Library
T4246L
T1657
External IDs
71
Properties
(calculated by RDKit )
Molecular Weight
211.11
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
0
Ring Count
4
Aromatic Ring Count
2
cLogP
1.8
TPSA
37.81
Fraction CSP3
0.38
Chiral centers
2.0
Largest ring
6.0
QED
0.72
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
nAChR
mAChR
¦Á4¦Â2 nAChR
ERK
p38 MAPK
MOA
AChR
AChR antagonist
Pathway
Neuroscience
Membrane Transporter/Ion Channel
Neuronal Signaling
MAPK/ERK Pathway
Stem Cell/Wnt
Source data